Yair Schneid Net Worth

The estimated Net Worth of Yair Schneid is at least 587 千$ dollars as of 29 January 2024. Yair Schneid owns over 932,402 units of Galera Therapeutics Inc stock worth over 587,154$ and over the last few years Yair sold GRTX stock worth over 0$.

Yair Schneid GRTX stock SEC Form 4 insiders trading

Yair has made over 1 trades of the Galera Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Yair bought 932,402 units of GRTX stock worth 167,832$ on 29 January 2024.

The largest trade Yair's ever made was buying 932,402 units of Galera Therapeutics Inc stock on 29 January 2024 worth over 167,832$. On average, Yair trades about 932,402 units every 0 days since 2024. As of 29 January 2024 Yair still owns at least 8,043,203 units of Galera Therapeutics Inc stock.

You can see the complete history of Yair Schneid stock trades at the bottom of the page.

What's Yair Schneid's mailing address?

Yair's mailing address filed with the SEC is 1, Wood Lane, Village of Suffern, Town of Ramapo, Rockland County, New York, 10901, United States.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over 19,201,067$ worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth 29,883,202$ . The most active insiders traders include Holdings A/S Novo、Group Inc Blackstone Group ...、Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of 11,809$. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth 4,691$.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Complete history of Yair Schneid stock trades at Galera Therapeutics Inc

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO